Impacting everything from cardiovascular to infectious diseases, you can help transform the way the world practices medicine. Backed by a multidisciplinary, institute-based philosophy, you’ll work alongside other talented caregivers to bring new ideas to the forefront and guarantee that we continue to deliver innovative healthcare.
This is the most exciting time to be in research. The things that we can do now in just a few hours used to take us months or years. The current pace of discovery is unprecedented and limited only by our imaginations.– Serpil Erzurum, MD, Chair, Lerner Research Institute
Lerner Research Institute.
Inside the Lerner Research Institute on our main campus, we’re equipping the brightest minds in medicine with what matters most — including leading-edge technologies and the support to tap into their highest potential. Each day here is an opportunity to share and exchange experience and knowledge, as well as develop your expertise through our various academic partnerships.
By the numbers.
Our team of nearly
2,000 scientists and support members
come together in
a 700,000-square-foot facility
to do research backed by
175 principal investigators
$140 million in federal funding.
With that assistance, our teams have been issued
Our latest research.
Dr. Lynn Bekris and her team have found a link between the gene variant TNFRSF1B and cognitive resilience to Alzheimer’s. The work can help establish new biomarkers and drug targets for treating the elusive disease.
Focal Cortical Dysplasia (FCD)
Patients with FCD — one of the most common causes of drug-resistant epilepsy — may be getting new insights into their condition from Dr. Dennis Lal and his team. They’ve just received a five-year, $3.3 million award from the National Institutes of Health to study the genetics of FCD.
Type 2 Diabetes
New personalized care options for Type 2 Diabetes patients may be on the way thanks to Dr. Daniel Rotroff and his team. They’ve discovered how a genetic variation can identify those patients at risk for greater cardiovascular disease requiring aggressive glycemia treatment.